A phase II trial for house dust mite rhinitis with a new improved hdm-ASIT+ product.

Trial Profile

A phase II trial for house dust mite rhinitis with a new improved hdm-ASIT+ product.

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Feb 2018 New trial record
    • 25 Jan 2018 According to an ASIT biotech media release, this trial is due to be initiated in early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top